Eyepoint outlines DURAVYU DME focus with COMO/CAPRI top line expected early Q4 2027

EyePoint reported a Q3 loss of $1.07 per share, missing estimates, with revenue of $0.76M. The company halted its wet AMD program after trial failures, focusing on DME. Cash reserves fell to $118M, and the company plans workforce reductions. DME trial results are expected in Q4 2027, but financing may be needed before then. Shares have dropped 97% since August.

EyePoint, Inc. (EYPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments – Organizational focus on DURAVYU TM Phase 3 DME program; trials fully enrolled with topline data expected in early Q4 2027 – – DURAVYU DME program supported by the posit

EyePoint Inc. (EYPT) announced full enrollment in its DME Phase III trials, with top-line data expected in early Q4 2027. The company aims to cut costs by 53% and save $30M annually after wet AMD trial setbacks. Management remains optimistic based on Phase II results and disease biology.

EyePoint Inc. (EYPT) reported that its phase III trials, LUGANO and LUCIA, missed the primary endpoint, but safety and other results were positive. The company has fully enrolled COMO and CAPRI trials, with readouts expected in early Q4 2027. The update was shared during the 3rd Annual Guggenheim Healthcare Innovation Conference.

EyePoint Pharmaceuticals cut 53% of its workforce and ended a Phase III trial for duravyu after it failed to meet the primary endpoint in a wet age-related macular degeneration study. The company will focus on duravyu's development for diabetic macular oedema, with topline data expected in Q4 2027. EyePoint's stock dropped over 80% following the announcement.

RBC Capital cut EyePoint Inc.'s (NASDAQ:EYPT) price target to $1.00 from $5.00 after its LUCIA trial failed, sending shares down 85%. The company's market cap fell to $37.93M. EyePoint is considering options for wAMD and maintains a cash runway into Q4 2027. Multiple firms downgraded EYPT following the trial results.